OpenAI Launches Longevity Model

Artificial intelligence is disrupting drug discovery.

The latest: OpenAI and longevity startup Retro Biosciences created an AI model for cellular reprogramming, the act of converting aging cells to younger, healthier versions (aka stem cells).

Optimizing AI-powered protein engineering, the GPT-4b model improves cellular rejuvenation efficiency by 50x.

Long game. Benefiting anti-aging science and his portfolio, OpenAI CEO Sam Altman previously invested $180M into Retro, laying the groundwork for the partnership.

Smart drugs. AI partnerships are shaking up drug development.

  • Venture firm a16z and pharma giant Eli Lilly launched a $500M AI x biotech fund.
  • Chipmaker NVIDIA teamed with IQVIA, Illumina, and Mayo Clinic for AI-powered genomics research.
  • Novo Nordisk expanded its AI drug discovery partnership with Valo Health, targeting obesity, diabetes, and cardiovascular disease

Seeking a competitive edge, the surge of tech-pharma alliances aims to slash long, expensive drug development cycles while ushering in a new era of personalized therapeutics.

Punchline: As artificial intelligence reshapes life as we know it, the marriage of Big Tech and biotech promises to treat disease until it can cure death, raising ethical questions along the way.

What’s happening now—and next—in health, fitness, and wellness.

Get the latest industry news and trends delivered every Tuesday — distilled to help you save time and spot new opportunities.

    No thanks.